Drugs / M-M-R(TM) II
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00092391 | Feb 1999 → Jul 2001 | chickenpox, measles, mumps infectious disease, rubella | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-03-06 | Merck Sharp & Dohme LLC | Regulatory US FDA Approves Intramuscular Administration for Merck’s MMRV Family of Vaccines: M-M-RII (Measles, Mumps, and Rubella Virus Vaccine Live), VARIVAX (Varicella Virus Vaccine Live), and ProQuad (Measles, Mumps, Rubella and Varicella Virus Vaccine Live) merck.com ↗
In the U.S., the only measles, mumps, rubella, and varicella vaccines that can be administered IM are M-M-R ® II , VARIVAX ® , and ProQuad ® . |
All press releases naming this drug 1 release
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M-M-R(TM) II | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00092391 ↗ |
| Known as | measles, mumps, and rubella virus vaccine live | “Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live” NCT00092391 ↗ |
| Modality | Vaccine | “measles, mumps, and rubella virus vaccine live” NCT00092391 ↗ |
| Route | Subcutaneous | “0.5 mL subcutaneous injection of one of three sub-lots on Day 0” NCT00092391 ↗ |